NCPC(SH:600812) Xin Lang Cai Jing·2026-01-04 23:46Group 1 - The application for Dapoxetine α injection by Terumo Corporation, Kofu Factory has been accepted by the National Medical Products Administration on January 5, 2026, with acceptance number JTS2600001 [1] - The drug Dapoxetine α injection is classified as a biological product and is under the import registration application type [1] - The companies involved in the application include Terumo Corporation, Kofu Factory, Kyowa Kirin Co., Ltd., and North China Pharmaceutical Jintan Biotechnology Co., Ltd. [1] Group 2 - North China Pharmaceutical Jintan Biotechnology Co., Ltd. was established on April 2, 2002, and is a medium-sized company with 619 insured employees [1] - The registered capital of North China Pharmaceutical Jintan Biotechnology Co., Ltd. is 1.85051637 billion RMB, with a paid-in capital of 1.63989152 billion RMB [1] - The major shareholder is North China Pharmaceutical Co., Ltd., holding 98% of the shares, while North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. holds 2% [1]